Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Blood (2024) 144 (Supplement 1): 6201.

https://doi.org/10.1182/blood-2024-205509

Published: 2024

Journal Articles

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Blood (2024) 144 (12): 1284–1289.

https://doi.org/10.1182/blood.2023023639

Published: 2024

Includes: Supplemental data

Journal Articles

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Blood (2023) 142 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2023-182874

Published: 2023

Journal Articles

Electrocardiogram As a Marker of Cardiac Response in Light Chain Amyloidosis

Rodrigo Fonseca, Yael Kusne, Mariano Arribas, Molly Klanderman, Julia E. Wiedmeier, Eli Muchtar, P. Leif Bergsagel, Craig B. Reeder, Jeremy T. Larsen, Rafael Fonseca, Julie L Rosenthal

Blood (2022) 140 (Supplement 1): 12566–12567.

https://doi.org/10.1182/blood-2022-168083

Published: 2022

Journal Articles

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Karan Chohan, Jonas Paludo, Surendra Dasari, Jithma P. Abeykoon, Prashant Kapoor, Esteban Braggio, Michelle K. Manske, Aneel Paulus, Craig B. Reeder, Sikander Ailawadhi, Asher Chanan-Khan, Robert A. Kyle, Morie A Gertz, Anne J. Novak, Stephen M. Ansell

Blood (2022) 140 (Supplement 1): 9242–9243.

https://doi.org/10.1182/blood-2022-167543

Published: 2022

Journal Articles

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic

Yael Kusne, Rodrigo Fonseca, Mariano Arribas, Molly Klanderman, Julia E. Wiedmeier, Craig B. Reeder, Jeremy T. Larsen, P. Leif Bergsagel, Julie L Rosenthal, Rafael Fonseca

Blood (2022) 140 (Supplement 1): 7224–7225.

https://doi.org/10.1182/blood-2022-166668

Published: 2022

Journal Articles

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2021-151859

Published: 2021

Journal Articles

"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience

Blood (2021) 138 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2021-147925

Published: 2021

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Mays F Abdulazeez, MBBS, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rahma M Warsame, MD, Jeremy Larsen, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Prashant Kapoor, MD, Rafael Fonseca, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Suzanne R. Hayman, MD, Craig B. Reeder, MD, Arshi Agrawal, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139929

Published: 2020

Journal Articles

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Craig B. Reeder, MD, Taimur Sher, MD, Vivek Roy, MD, Rahma M Warsame, MD, Victoria R. Alegria, Wilson I Gonsalves, MD, Prashant Kapoor, MD, David Dingli, MD PhD, Suzanne R. Hayman, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139559

Published: 2020

Journal Articles

Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

Madiha Iqbal, MBBS, Yennifer Gil, Jonas Paludo, MD, Allison C. Rosenthal, D.O., Zhou Li, MS, Manuel Beltran, David J. Inwards, MD, Luis F. Porrata, MD, Ivana Micallef, MD, Jose C Villasboas, MD, Patrick B. Johnston, Stephen M. Ansell, MD PhD, Craig B. Reeder, MD, Hemant S. Murthy, MD, Vivek Roy, MD, James M. Foran, MD, Han W. Tun, MD, Mohamed A. Kharfan-Dabaja, MDMBA, Ernesto Ayala, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136332

Published: 2020

Journal Articles

Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma

Miguel Gonzalez-Velez, MD, Mariano Arribas, Heidi E. Kosiorek, MS, Richard Butterfield, III, Carlo Guerrero, MD, Luke Mountjoy, DO, Jeremy Larsen, Craig B. Reeder, MD, P. Leif Bergsagel, MD, A. Keith Stewart, MB, ChB, Rafael Fonseca, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-142845

Published: 2020

Journal Articles

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1904.

https://doi.org/10.1182/blood-2019-131478

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Jonas Paludo, MD, Surendra Dasari, PhD, Kerstin Wenzl, PhD, Shahrzad Jalali, PhD, Jordan Krull, Michelle Manske, MS, BS, Esteban Braggio, PhD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, MD, Craig B. Reeder, MD, Allison C. Rosenthal, DO, Robert A. Kyle, MD, Morie A Gertz, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2774.

https://doi.org/10.1182/blood-2019-128912

Published: 2019

Journal Articles

Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia

Jonas Paludo, MD, Jithma Prasad Abeykoon, MD, Stephen M. Ansell, MD PhD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Craig B. Reeder, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Anne J Novak, PhD, Francis K. Buadi, MB, CHB, Angela Dispenzieri, MD, Yi Lin, MD PhD, Martha Q. Lacy, MD, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Robert A. Kyle, MD, Ronald S. Go, MD

Blood (2018) 132 (Supplement 1): 622.

https://doi.org/10.1182/blood-2018-99-111517

Published: 2018

Journal Articles

Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)

Jonas Paludo, MD, Jose Villasboas Bisneto, MD, Anne J Novak, PhD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Esteban Braggio, PhD, Craig B. Reeder, MD, Shahrzad Jalali, PhD, Francis K. Buadi, MB, CHB, Robert A. Kyle, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 4138.

https://doi.org/10.1182/blood-2018-99-117568

Published: 2018

Journal Articles

Depth of Response in Waldenstrom Macroglobulinemia

Jonas Paludo, MD, Jithma Prasad Abeykoon, MD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Craig B. Reeder, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Anne J Novak, PhD, Francis K. Buadi, MB, CHB, Angela Dispenzieri, MD, Yi Lin, MD PhD, Ronald S. Go, MD, Martha Q. Lacy, MD, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Robert A. Kyle, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 4141.

https://doi.org/10.1182/blood-2018-99-111540

Published: 2018

Journal Articles

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Nancy L. Bartlett, MD, Robert W. Chen, MD, Eva Domingo-Domenech, MD, Andres Forero-Torres, MD, Ramon Garcia-Sanz, MD PhD, Philippe Armand, MD PhD, Sumana Devata, MD, Antonia Rodriguez Izquierdo, MD, Izidore S. Lossos, MD, Craig B. Reeder, MD, Taimur Sher, MD, Cassandra Choe-Juliak, MD MS, Kim Prier, Sylvia Schwarz, PhD, Andras Strassz, MD, Leila Alland, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2018-99-118506

Published: 2018

Journal Articles

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma

Han W. Tun, Patrick B. Johnston, Lisa M. DeAngelis, Pamela J. Atherton, Levi D. Pederson, Patricia A. Koenig, Craig B. Reeder, Antonio M. Padula Omuro, David Schiff, Brian O’Neill, Jose Pulido, Kurt A. Jaeckle, Christian Grommes, Thomas E. Witzig

Blood (2018) 132 (21): 2240–2248.

https://doi.org/10.1182/blood-2018-02-835496

Published: 2018

Includes: Supplemental data

NARROW

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Electrocardiogram As a Marker of Cardiac Response in Light Chain Amyloidosis

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia

Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)

Depth of Response in Waldenstrom Macroglobulinemia

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only